6533b825fe1ef96bd1282843
RESEARCH PRODUCT
The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
Christoph DüberAline Mähringer-kunzRoman KloecknerSchmidtmann IrenePeter R. GalleJan B. HinrichsArndt WeinmannVerena SteinleFelix HahnHauke LangSebastian Schottensubject
Malemedicine.medical_treatmentvirusesCancer TreatmentCardiovascular MedicineVascular MedicineDiagnostic RadiologyCohort Studies0302 clinical medicineMedical ConditionsMedicine and Health SciencesMedicineVenous ThrombosisMultidisciplinaryPortal VeinLiver DiseasesRadiology and ImagingSelective internal radiation therapyLiver NeoplasmsQRHematologyMiddle AgedTumor ResectionThrombosisMagnetic Resonance ImagingTreatment OutcomeSurgical OncologyOncologyCardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyFemaleRadiologyAnatomyLiver cancermedicine.drugResearch ArticleHepatic ResectionSorafenibAdultClinical Oncologymedicine.medical_specialtyCarcinoma HepatocellularImaging TechniquesScienceCardiologyRadiation TherapySurgical and Invasive Medical ProceduresGastroenterology and HepatologyResearch and Analysis MethodsVeins03 medical and health sciencesDigestive System ProceduresDiagnostic MedicineGastrointestinal TumorsHumansChemoembolization TherapeuticPortal VeinsBlood CoagulationAgedRetrospective StudiesSurgical ResectionCoagulation Disordersbusiness.industryProportional hazards modelCarcinomaCancers and NeoplasmsBiology and Life SciencesThrombosisHepatocellular Carcinomamedicine.diseaseSurvival AnalysisRadiation therapyCardiovascular AnatomyBlood VesselsClinical MedicinebusinessComplicationdescription
Background Portal vein tumor thrombosis (PVTT) is a frequent complication of hepatocellular carcinoma (HCC), which leads to classification as advanced stage disease (regardless of the degree of PVTT) according to the Barcelona Clinic Liver Cancer Classification. For such patients, systemic therapy is the standard of care. However, in clinical reality, many patients with PVTT undergo different treatments, such as resection, transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), or best supportive care (BSC). Here we examined whether patients benefited from such alternative therapies, according to the extent of PVTT. Methods This analysis included therapy-naïve patients with HCC and PVTT treated between January 2005 and December 2016. PVTT was classified according to the Liver Cancer study group of Japan as follows: Vp1 = segmental PV invasion; Vp2 = right anterior or posterior PV; Vp3 = right or left PV; Vp4 = main trunk. Overall survival (OS) was analyzed for each treatment subgroup considering the extent of PVTT. We performed Cox regression analysis with adjustment for possible confounders. To further attenuate selection bias, we applied propensity score weighting using the inverse probability of treatment weights. Results A total of 278 treatment-naïve patients with HCC and PVTT were included for analysis. The median observed OS in months for each treatment modality (resection, TACE/SIRT, sorafenib, BSC, respectively) was 32.4, 8.1, N/A, and 1.7 for Vp1; 10.7, 6.9, 5.5, and 1.2 for Vp2; 6.6, 7.5, 2.9, and 0.6 for Vp3; and 8.0, 3.6, 5.3, and 0.7 for Vp4. Thus, the median OS in the resection group in case of segmental PVTT (Vp1) was significantly longer compared to any other treatment group (all p values <0.01). Conclusions Treatment strategy for HCC with PVTT should not be limited to systemic therapy in general. The extent of PVTT should be considered when deciding on treatment alternatives. In patients with segmental PVTT (Vp1), resection should be evaluated.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-10-29 | PLoS ONE |